多参数MRI与经直肠超声引导穿刺在前列腺癌诊断中的准确性(PROMIS):配对验证确认性研究
PROMIS为多中心配对队列确认性研究,纳入740例PSA≤15 ng/mL、无既往穿刺史的男性,576例完成1.5特斯拉多参数MRI后行经直肠超声引导穿刺和模板前列腺穿刺活检。以模板穿刺活检为参考,临床显著癌定义为Gleason评分≥4+3或最大癌核心长度≥6 mm,多参数MRI敏感性93%(95%CI 88-96%)高于经直肠超声引导穿刺的48%(42-55%),特异性41%(36-46%)低于后者的96%(94-98%)。作者认为多参数MRI分诊可使27%患者避免首次穿刺、减少5%临床不显著癌诊断,若后续穿刺由MRI结果引导,可多检出最多18%临床显著癌。
要点
- 临床显著癌定义为Gleason评分≥4+3或最大癌核心长度≥6 mm,模板前列腺穿刺活检为参考标准。
- 多参数MRI对临床显著癌敏感性93%(95%CI 88-96%),经直肠超声引导穿刺为48%(42-55%),p<0.0001。
- 多参数MRI特异性41%(36-46%),经直肠超声引导穿刺为96%(94-98%),p<0.0001。
- 作者认为多参数MRI分诊可使27%患者避免首次穿刺,减少5%临床不显著癌诊断。
- 740例中44例(5.9%)报告严重不良事件,包括8例脓毒症。
适用人群与场景
- 前列腺特异性抗原浓度不超过15 ng/mL、无既往穿刺史的男性。
诊断标准与关键阈值
- 临床显著癌定义为Gleason评分≥4+3或最大癌核心长度6 mm或更长。
- 参考标准为模板前列腺穿刺活检(TPM-biopsy)。
研究设计与关键结果
- 多中心、配对队列、确认性研究,纳入740例男性,其中576例完成1.5特斯拉多参数MRI后行经直肠超声引导穿刺和模板前列腺穿刺活检。
- 模板前列腺穿刺活检显示408/576(71%)有癌,230/576(40%)为临床显著癌。
- 对临床显著癌,多参数MRI敏感性93%(95%CI 88-96%),经直肠超声引导穿刺48%(42-55%),p<0.0001;多参数MRI特异性41%(36-46%),经直肠超声引导穿刺96%(94-98%),p<0.0001。
- 740例中44例(5.9%)报告严重不良事件,包括8例脓毒症。
- 作者认为多参数MRI分诊可使27%患者避免首次穿刺,减少5%临床不显著癌诊断;若后续经直肠超声引导穿刺由MRI结果引导,与全部行经直肠超声引导穿刺的标准路径相比,可多检出最多18%的临床显著癌。
证据类型、等级与局限
- 证据类型:多中心配对队列确认性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,多参数MRI作为首次前列腺穿刺前的分诊试验,可减少约四分之一不必要的穿刺,并减少临床不显著前列腺癌的过度诊断、改善临床显著癌的检出。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Men with high serum prostate specific antigen usually undergo transrectal ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects including bleeding, pain, and infection. Multi-parametric magnetic resonance imaging (MP-MRI) used as a triage test might allow men to avoid unnecessary TRUS-biopsy and improve diagnostic accuracy.
METHODS: We did this multicentre, paired-cohort, confirmatory study to test diagnostic accuracy of MP-MRI and TRUS-biopsy against a reference test (template prostate mapping biopsy [TPM-biopsy]). Men with prostate-specific antigen concentrations up to 15 ng/mL, with no previous biopsy, underwent 1·5 Tesla MP-MRI followed by both TRUS-biopsy and TPM-biopsy. The conduct and reporting of each test was done blind to other test results. Clinically significant cancer was defined as Gleason score ≥4 + 3 or a maximum cancer core length 6 mm or longer. This study is registered on ClinicalTrials.gov, NCT01292291.
FINDINGS: Between May 17, 2012, and November 9, 2015, we enrolled 740 men, 576 of whom underwent 1·5 Tesla MP-MRI followed by both TRUS-biopsy and TPM-biopsy. On TPM-biopsy, 408 (71%) of 576 men had cancer with 230 (40%) of 576 patients clinically significant. For clinically significant cancer, MP-MRI was more sensitive (93%, 95% CI 88-96%) than TRUS-biopsy (48%, 42-55%; p<0·0001) and less specific (41%, 36-46% for MP-MRI vs 96%, 94-98% for TRUS-biopsy; p<0·0001). 44 (5·9%) of 740 patients reported serious adverse events, including 8 cases of sepsis.
INTERPRETATION: Using MP-MRI to triage men might allow 27% of patients avoid a primary biopsy and diagnosis of 5% fewer clinically insignificant cancers. If subsequent TRUS-biopsies were directed by MP-MRI findings, up to 18% more cases of clinically significant cancer might be detected compared with the standard pathway of TRUS-biopsy for all. MP-MRI, used as a triage test before first prostate biopsy, could reduce unnecessary biopsies by a quarter. MP-MRI can also reduce over-diagnosis of clinically insignificant prostate cancer and improve detection of clinically significant cancer.
FUNDING: PROMIS is funded by the UK Government Department of Health, National Institute of Health Research-Health Technology Assessment Programme, (Project number 09/22/67). This project is also supported and partly funded by UCLH/UCL Biomedical Research Centre and The Royal Marsden and Institute for Cancer Research Biomedical Research Centre and is coordinated by the Medical Research Council Clinical Trials Unit (MRC CTU) at UCL. It is sponsored by University College London (UCL).
参考来源
- Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017. PMID: 28110982. doi:10.1016/S0140-6736(16)32401-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。